Literature DB >> 28042021

Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.

Ryosuke Hosokai1, Masayoshi Masuko2, Yasuhiko Shibasaki2, Akihiko Saitoh1, Tatsuo Furukawa3, Chihaya Imai4.   

Abstract

Natural killer cells have been identified as a mediator of alloimmune reactions in allogeneic hematopoietic stem cell transplantation (HSCT). Killer immunoglobulin-like receptors (KIRs) are an important determinant of natural killer cell function. The relationship between KIR genotypes/haplotypes and clinical outcomes of allogeneic HSCT is complex and inconsistent among several reports. We assessed the clinical impact of KIR haplotype on T cell-replete allogeneic HSCTs performed in a single Japanese center for hematological malignancies (n = 106). A comparison of 2 groups, donor haplotypes A/A and B/x, revealed no significant differences in overall survival, relapse, and nonrelapse mortality. However, grade III to IV acute graft-versus-host disease (GVHD) occurred significantly more frequently in the KIR haplotype B/x group (A/A versus B/x: 4.9% versus 20.0%; P = .02). This was even more evident when HLA mismatch was present. The highest incidences of grade II to IV and grade III to IV acute GVHD were observed in patients who received allografts from HLA-mismatched donors with KIR haplotype B/x. These data highlight the importance of KIR genotyping in donor matching, especially when HLA mismatch allogeneic grafting is planned.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute graft-versus-host disease; Allogeneic hematopoietic cell transplantation; Killer immunoglobulin-like receptor haplotype

Mesh:

Substances:

Year:  2016        PMID: 28042021     DOI: 10.1016/j.bbmt.2016.12.638

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

Review 1.  NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Authors:  Catharina H M J Van Elssen; Stefan O Ciurea
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

Review 2.  The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia.

Authors:  Alireza Zafarani; Mahsa Taghavi-Farahabadi; Mohammad Hossein Razizadeh; Mohammad Reza Amirzargar; Mansoure Mansouri; Mohammad Mahmoudi
Journal:  Stem Cell Rev Rep       Date:  2022-08-22       Impact factor: 6.692

Review 3.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

Review 4.  The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.

Authors:  Stefan O Ciurea; Monzr M Al Malki; Piyanuch Kongtim; Ephraim J Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Patrick Ben Soussan; Yolande Arnault; Rupert Handgretinger; Denis-Claude Roy; Paul V O'Donnell; Asad Bashey; Scott Solomon; Rizwan Romee; Jorge Gayoso; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2019-03-04       Impact factor: 5.483

5.  Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Yanmin Zhao; Fei Gao; Yibo Wu; Jimin Shi; Yi Luo; Yamin Tan; Jian Yu; Xiaoyu Lai; Mingming Zhang; Wei Zhang; He Huang
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

6.  Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.

Authors:  Tsutomu Nakazawa; Takayuki Morimoto; Ryosuke Maeoka; Ryosuke Matsuda; Mitsutoshi Nakamura; Fumihiko Nishimura; Shuichi Yamada; Ichiro Nakagawa; Young-Soo Park; Hiroyuki Nakase; Takahiro Tsujimura
Journal:  Regen Ther       Date:  2022-07-21       Impact factor: 3.651

Review 7.  Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Authors:  Fei Gao; Yishan Ye; Yang Gao; He Huang; Yanmin Zhao
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

8.  KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Cynthia Vierra-Green; Stephen Spellman; Jennifer A Sees; Ashley Spahn; Jenny Vogel; Todd A Fehniger; Ann E Woolfrey; Steven M Devine; Maureen Ross; Edmund K Waller; Ronald M Sobecks; Joseph McGuirk; Betul Oran; Sherif S Farag; Tsiporah Shore; Koen Van Besien; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller
Journal:  Blood Adv       Date:  2020-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.